HD-OPM Archive

Newer lipid drugs: bempedoic acid, obicetrapib and what's coming

A plain-language tour of the LDL- and Lp(a)-lowering drugs beyond statins and ezetimibe - bempedoic acid, PCSK9 drugs, the newly approved CETP inhibitor obicetrapib, and the triglyceride and Lp(a) drugs in the pipeline - and what the evidence does and does not show about each.

16 min read30 group posts cited30 studies discussed5 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Bempedoic acid lowered LDL-C by about 21% and hsCRP by about 21.5% in a 4,206-person statin-intolerant primary prevention analysis, where the main composite of cardiovascular events fell 30% (HR 0.70), at the cost of more gout and gallstones.1
  • Obicetrapib, a low-dose oral CETP inhibitor, received the first approval anywhere (European Commission, 21 September 2026), with reported LDL-C reductions of about 40% alone and about 50% combined with ezetimibe; its heart-attack and stroke outcome results are still awaited.23
  • Earlier CETP inhibitors and niacin raised HDL and lowered LDL yet did not cut events (torcetrapib even raised deaths from 59 to 93), which is why the admins insist that outcome trials, not blood-test changes alone, decide whether a drug works.456
  • Olezarsen cut triglycerides about 64% and remnant cholesterol about 72% but did not change plaque over 12 months, and the Lp(a) drug pelacarsen lowered Lp(a) sharply yet event rates were 12.3% versus 12.1% on placebo.47
  • Lepodisiran lowered Lp(a) by 93.9% at the 400 mg dose in a 320-person phase 2 trial, but whether lowering Lp(a) prevents heart attacks remains unproven.89
  • PCSK9 antibodies (about 50-60% LDL-C reduction) have proven outcome benefit only on top of statins, so guidelines keep statins first and add the newer drugs in steps.1011
In this summary
  1. The drugs at a glance
  2. Where the newer drugs fit: the stepwise approach
  3. Bempedoic acid
  4. PCSK9 antibodies and inclisiran
  5. Obicetrapib and the CETP story
  6. Triglyceride and remnant drugs: olezarsen
  7. Lp(a) drugs: pelacarsen and lepodisiran
  8. Nuances and common misconceptions
  9. What this means for you
  10. Frequently asked questions
  11. The evidence behind this summary

Statins remain the foundation of cholesterol lowering, and ezetimibe is the usual first add-on. But a growing set of other drugs now exist for people who cannot take statins, who still have high LDL after statins, or who have a problem statins do not touch, such as high lipoprotein(a), or Lp(a). This article covers the main ones in the group's discussions: bempedoic acid, the PCSK9 drugs and inclisiran, the CETP inhibitor obicetrapib, the triglyceride drug olezarsen, and the Lp(a)-lowering drugs pelacarsen and lepodisiran.

The short answer is that these drugs differ greatly in how much evidence stands behind them. Some, like the PCSK9 antibodies, lower LDL by half or more and have outcome-trial support when added to statins. Bempedoic acid has outcome data in statin-intolerant people. Others, like obicetrapib, lepodisiran and olezarsen, lower a number on a blood test impressively, but it is not yet known (or in some cases it has been disappointing) whether that translates into fewer heart attacks.

A theme runs through the group's coverage: lowering a lab number is not the same as lowering risk. Louis Nervegna, one of the group's admins, repeatedly stresses that a drug must show fewer events in large randomized trials before one can assume it protects the heart.5 The sections below follow that principle, and nothing here is personal medical advice; the group's admins consistently suggest discussing options with your own doctor.

30%fewer cardiovascular events on bempedoic acid in 4,206 statin-intolerant people1
40% / 50%LDL-C reduction reported for obicetrapib alone and with ezetimibe, approved in the EU in September 20262
93.9%drop in Lp(a) with lepodisiran 400 mg in a 320-person trial, with no outcome data yet8
12.3% vs 12.1%events on pelacarsen versus placebo, despite a sharp fall in Lp(a)4

The drugs at a glance

DrugWhat it targetsEffect on its target, as reportedOutcome evidence in the posts
Bempedoic acid (oral)LDL-CAbout 23% alone, 38% with ezetimibe1030% fewer events in statin-intolerant people1
PCSK9 antibodies (injection)LDL-CAbout 50–60%10Fewer events, on top of statins only11
Inclisiran (injection twice a year)LDL-C (siRNA)Not given in the postsNot given in the posts
Obicetrapib (oral)CETP, LDL-CAbout 40% alone, 50% with ezetimibe2Results awaited3
OlezarsenAPOC3, triglyceridesTriglycerides about 64% lower7No change in plaque at 12 months7
PelacarsenLp(a)Median 64 versus 233 nmol/L4No fewer events (12.3% versus 12.1%)4
LepodisiranLp(a) (siRNA)93.9% lower8Not yet shown9

Where the newer drugs fit: the stepwise approach

Guidelines generally treat these drugs as add-ons rather than replacements. A shared summary of the 2025 ESC/EAS dyslipidaemia guideline update describes a stepwise approach.10

  • Ezetimibe is the first-line oral add-on, lowering LDL-C by about 20%.
  • Bempedoic acid is an oral option for statin intolerance, lowering LDL-C by about 23% alone and about 38% together with ezetimibe.
  • PCSK9 monoclonal antibodies are high-efficacy injectables (about 50-60% reduction) for very-high-risk patients.
  • Inclisiran is an siRNA (a small RNA-based medicine) given by injection twice a year, aimed at long-term adherence.

For people who have just had a heart attack or other acute coronary syndrome (ACS), Louis summarizes the 2025 ACC/AHA ACS guideline this way: high-intensity statin for everyone, with the option of starting ezetimibe at the same time. A non-statin agent (ezetimibe, evolocumab, alirocumab, inclisiran or bempedoic acid) is recommended if LDL-C is still 70 mg/dL (1.8 mmol/L) or higher on a maximally tolerated statin, and it is described as "reasonable" to intensify further when LDL-C is 55 to under 70 mg/dL.12 Louis also posted a short list of the most effective statin alternatives: ezetimibe, bempedoic acid, inclisiran, Repatha (evolocumab) and Praluent (alirocumab).13

Ezetimibe itself is covered elsewhere in the archive, but one data point is worth noting here because it shows the logic of stacking drugs. In a study of 299 people with ACS, LDL-C fell 44.4% on a high-intensity statin, 55.5% when rosuvastatin was combined with ezetimibe, and 62.2% when bempedoic acid was added as a third drug; the share reaching LDL below 70 mg/dL rose from 81.6% to 88.7% to 95.2%.14

Stacking drugs stacks the LDL dropLDL-C reduction after 4 weeks in 299 people with an acute coronary syndrome
High-intensity statin44.4%
Rosuvastatin + ezetimibe55.5%
Rosuvastatin + ezetimibe + bempedoic acid62.2%
Share reaching LDL-C below 70 mg/dL: 81.6%, 88.7% and 95.2%. Source: 14
Show data
Value
High-intensity statin44.4%
Rosuvastatin + ezetimibe55.5%
Rosuvastatin + ezetimibe + bempedoic acid62.2%

Bempedoic acid

Bempedoic acid is an oral once-daily tablet that lowers LDL-C and is used mainly by people who cannot tolerate statins, or alongside them.1013 The group's main data point comes from a summary written by Gokhan Can and shared by Louis. It describes an outcomes analysis in 4,206 statin-intolerant, high-risk primary prevention patients given bempedoic acid 180 mg daily or placebo.1

  • The main composite (cardiovascular death, nonfatal heart attack, nonfatal stroke or coronary revascularization) fell 30% (HR 0.70, 95% CI 0.55-0.89).
  • Cardiovascular death, heart attack or stroke fell 36% (HR 0.64).
  • Heart attack fell 39% (HR 0.61), cardiovascular death fell 39% (HR 0.61), and all-cause mortality fell 27% (HR 0.73, 95% CI 0.54-0.98).
  • LDL-C fell 21.3% and high-sensitivity C-reactive protein (hsCRP, a blood marker of inflammation) fell 21.5%.
  • Side effects included more gout and gallstones, and higher creatinine, uric acid and liver enzyme levels.
Bempedoic acid cut events in statin-intolerant peopleBempedoic acid 180 mg daily versus placebo, 4,206 statin-intolerant high-risk primary prevention patients
interval clear of 195% confidence interval
Main composite (CV death, heart attack, stroke or revascularization)0.70 (0.55–0.89)
CV death, heart attack or stroke0.64
Heart attack0.61
Cardiovascular death0.61
All-cause mortality0.73 (0.54–0.98)
Confidence intervals are shown where the post gives them. Source: 1
Show data
Hazard ratio95% CI
Main composite (CV death, heart attack, stroke or revascularization)0.700.55–0.89
CV death, heart attack or stroke0.64–
Heart attack0.61–
Cardiovascular death0.61–
All-cause mortality0.730.54–0.98

The same post notes laboratory work in which an enzyme that bempedoic acid blocks, ACLY, drives age-related "senescence" inflammation in aged mice. The post's framing of bempedoic acid as a "potential life extension drug" is speculative and rests on animal data, not human trials.1

Louis's hsCRP summary adds another angle. Drawing on a meta-analysis in Cardiovascular Research, he lists average hsCRP reductions of about 20% for bempedoic acid, 17.3% for statins, 10.3% for fibrates, 6% for PCSK9 inhibitors and 3.2% for ezetimibe. The paper's own illustration, shared in the same post, shows PCSK9 inhibitors slightly raising hsCRP (about +6%) rather than lowering it, and the fibrate reduction as not statistically significant.15 Gokhan highlighted the same paper, which concluded that statins, bempedoic acid, ezetimibe and omega-3 fatty acids reduce CRP independently of how much they lower LDL-C.16 Whether lowering hsCRP itself translates into extra benefit is a separate question the posts do not settle.

A post by Louis (written with AI help) names the CLEAR Outcomes trial as showing fewer cardiovascular events with bempedoic acid in statin-intolerant patients, in contrast with PCSK9 drugs, for which no dedicated statin-free outcome trial exists.11

PCSK9 antibodies and inclisiran

PCSK9 antibodies (Repatha and Praluent) lower LDL-C by roughly 50-60%, and inclisiran works by a different route (siRNA) and is dosed twice yearly.10 The most important caution comes from Louis: the landmark outcome trials (FOURIER and VESALIUS-CV for Repatha, ODYSSEY OUTCOMES for Praluent) tested the drugs on top of statins. No dedicated outcomes trial has shown fewer heart attacks or strokes for these drugs used alone. The monotherapy trials in statin-intolerant people measured LDL-C and tolerability rather than events. Guidelines therefore keep statins first and recommend PCSK9 drugs on their own only for people who cannot take statins. Louis warns that influencers who suggest replacing statins with PCSK9 drugs are going beyond the evidence.11

Louis also posted about early research suggesting PCSK9 inhibition may slow cardiometabolic aging, based on a GeroScience review and a genome-wide analysis of aging traits. He describes it as an emerging area, not an established benefit.17

Obicetrapib and the CETP story

Why earlier CETP drugs failed

CETP (cholesteryl ester transfer protein) moves cholesterol between HDL and LDL particles; blocking it raises HDL cholesterol and lowers LDL cholesterol. Louis explains that the first wave of CETP inhibitors was promising on blood tests but not on outcomes.518 A summary he endorsed lists the HDL-raising failures:6

  • AIM-HIGH (niacin): HDL up 25%, no fewer events, stopped early for futility.
  • HPS2-THRIVE (niacin plus laropiprant): HDL up, no fewer major vascular events, more serious adverse events.
  • dal-OUTCOMES (dalcetrapib): HDL up 31%, no reduction in events.
  • ILLUMINATE (torcetrapib): HDL up 72%, with cardiovascular death increased.
  • ACCELERATE (evacetrapib): HDL up 130%, no reduction in major adverse cardiovascular events.
HDL went up, events did not come downRise in HDL cholesterol in HDL-raising outcome trials that failed to reduce cardiovascular events
AIM-HIGH (niacin)+25%
dal-OUTCOMES (dalcetrapib)+31%
ILLUMINATE (torcetrapib)+72%
ACCELERATE (evacetrapib)+130%
Torcetrapib (ILLUMINATE) increased cardiovascular deaths. Source: 6
Show data
Value
AIM-HIGH (niacin)+25%
dal-OUTCOMES (dalcetrapib)+31%
ILLUMINATE (torcetrapib)+72%
ACCELERATE (evacetrapib)+130%

A later post gives numbers for torcetrapib (15,067 high-risk patients; deaths rose from 59 to 93 and the trial was stopped) and for dalcetrapib (events 8.3% versus 8.0%).4 Louis's earlier review reached the same conclusion for ApoA-I, the main protein in HDL: drugs and infusions that raised it did not help, and Mendelian randomization (a genetic method that uses inherited variants as a natural experiment) agrees.19

His interpretation is that HDL is largely a marker of insulin sensitivity. Risk falls when HDL rises because insulin sensitivity improves, not because of the HDL itself, though he allows that some HDL subfractions might still prove protective.620

What is different about obicetrapib

Obicetrapib is a low-dose oral CETP inhibitor made by NewAmsterdam Pharma. Louis says it appears to avoid some problems of the earlier drugs and that it is being developed mainly for its ability to lower LDL-C and other atherogenic (plaque-forming) lipoproteins.221

  • Regulatory status: on 21 September 2026 the European Commission granted marketing authorization, described as the first approval anywhere, for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg).2
  • LDL lowering: the company reports reductions of up to about 40% alone and about 50% with ezetimibe compared with placebo, with tolerability comparable to placebo. In the BROADWAY trial (adults with cardiovascular disease on maximally tolerated lipid therapy, 10 mg for one year) the LDL-C reduction was 29.9%.222
  • Other lipids: a study in high-risk people already on statins found meaningful reductions in LDL-C and other atherogenic lipids with higher HDL-C.3
  • Not yet proven: Louis wants to see whether this translates into fewer heart attacks and deaths. The post announcing EU approval is explicit that obicetrapib is not approved for Alzheimer's treatment or prevention.23

The Alzheimer's angle

Much of the group's interest in obicetrapib is about the brain, particularly for carriers of the APOE4 gene variant. A BROADWAY substudy reported at an Alzheimer's conference found that obicetrapib reduced p-tau217, an Alzheimer's blood biomarker, with the largest effect in APOE4 carriers. The analysis included 1,535 participants with known APOE status, 367 of them APOE4 carriers, and in people with two APOE4 copies p-tau217 was 20.5% lower than on placebo.22 Another post lists five biomarkers that moved favorably (p-tau217, Abeta42/40, the p-tau217/Abeta ratio, GFAP and NfL), with placebo-adjusted benefits of 13.67 to 22.65%.23 A phase 2 prevention trial is planned in which about 75% of participants will be APOE4 carriers.21

There are important caveats, some stated by the posts themselves:

  • These are biomarker results, not memory or dementia outcomes, in a subgroup that needs replication.23
  • Posts describe the analysis differently: one calls it prespecified, another post hoc.1822
  • The researchers quoted believe the effect may come from raised HDL as well as lowered LDL, while another quote suggests much of the benefit may simply reflect better cardiovascular health.1822

Louis also shared genetic evidence (a 2024 Mendelian randomization on CETP variants and dementia, with early supportive findings from centenarian and cohort studies), but the post itself states this is early and not proof of clinical benefit.24

Triglyceride and remnant drugs: olezarsen

Olezarsen is an RNA-targeted drug that inhibits APOC3 and lowers triglycerides. In an imaging study it reduced triglycerides about 64%, remnant cholesterol about 72% and ApoB about 16% versus placebo, with no change in LDL-C. Yet 12-month CT angiography showed no difference in non-calcified, low-attenuation or total plaque (primary endpoint p=0.36), and 97% of participants were already on therapy.725 (Different posts call this result BRIDGE-TIMI 73a and ESSENCE-TIMI 73b.)726

Louis's reading is that lowering high triglycerides without treating the underlying insulin resistance does not slow plaque growth. He argues that unless triglycerides are above about 400-500 mg/dL, lowering them with drugs makes little difference to plaque or hard outcomes, and that ApoB already captures the risk carried by VLDL particles.726 The post notes that very severe hypertriglyceridemia still raises pancreatitis risk.26 Ethan Weiss, quoted by Gokhan, called it one of the most interesting null results in a long time.25 A cardiologist commentary in the shared material pointed to possible methodological flaws, such as heavy background treatment and short follow-up, so the question is not entirely closed.7

Olezarsen: big lipid changes, no plaque changeChange versus placebo with olezarsen; coronary plaque on CT angiography at 12 months did not differ (p=0.36)
Triglyceridesabout −64%
Remnant cholesterolabout −72%
ApoBabout −16%
LDL-C was unchanged; 97% of participants were already on therapy. Source: 7
Show data
Value
Triglyceridesabout −64%
Remnant cholesterolabout −72%
ApoBabout −16%

Lp(a) drugs: pelacarsen and lepodisiran

Lp(a) is an LDL-like particle with an extra protein tail (apolipoprotein(a)). It is largely set by genes, roughly one in five people have a high level, and statins, ezetimibe, fibrates and fish oil do not lower it. New drugs lower it by 80 to 99%, but the posts note that lower numbers had not been proven to prevent heart attacks.9 Genetic estimates suggest that, particle for particle, Lp(a) carries about six times the risk of LDL.927

  • Lepodisiran: an siRNA that blocks liver production of Lp(a). In an NEJM trial of 320 people, the 400 mg dose lowered Lp(a) by a placebo-adjusted 93.9% (days 60-180), lasting up to a year, with only mild injection-site reactions.8
  • Pelacarsen: in Lp(a)HORIZON (8,322 people with prior heart attack, stroke or peripheral artery disease), median Lp(a) was 64 versus 233 nmol/L after one year, but over 4.7 years the main event composite occurred in 12.3% versus 12.1% on placebo.4

A Nature news feature that Louis shared explores why the trial may have been neutral. Experts quoted raised several possibilities: participants were already very well treated, with some of the lowest LDL levels ever seen in a randomized trial, so aggressive LDL lowering may have blunted Lp(a) risk. Four or five years of treatment may be too short, or treatment may have started too late. Subgroups, such as people with the highest Lp(a) or those not on antiplatelet drugs, still need examination.27 The shared NEJM summary adds that the trial does not prove Lp(a) is non-causal, since it enrolled people who already had disease.4 Lepodisiran's own outcome benefit has not been shown, and the group's Lp(a) explainer likewise says trials designed to answer the question were still reporting.9

The graphic shared with the NEJM results: pelacarsen lowered Lp(a) (64 versus 233 nmol/L) and ziltivekimab lowered CRP by 64% and IL-6 by 76%, yet major heart events were 12.3% versus 12.1% in Lp(a)HORIZON and 17.6% versus 17.7% in ZEUS.
The graphic shared with the NEJM results: pelacarsen lowered Lp(a) (64 versus 233 nmol/L) and ziltivekimab lowered CRP by 64% and IL-6 by 76%, yet major heart events were 12.3% versus 12.1% in Lp(a)HORIZON and 17.6% versus 17.7% in ZEUS.4

Nuances and common misconceptions

  • A lab improvement is not a clinical benefit. Niacin and CETP inhibitors lowered LDL and changed HDL, and still failed. Louis notes this is why the FDA requires large outcome trials for a heart-attack-prevention indication.5 The same pattern recurred recently with pelacarsen and with ziltivekimab, which cut CRP by 64% and IL-6 by 76% but produced event rates of 17.6% versus 17.7%.4
  • Newer is not automatically better. PCSK9 drugs may work as well as or better than statins, but the honest answer, according to Louis, is that this has not been shown.11
  • Non-statin drugs act in the blood, not the brain. Louis explains that PCSK9 inhibitors, ezetimibe and bempedoic acid do not influence brain cholesterol production, because the brain makes its own cholesterol separately, whereas lipophilic statins such as atorvastatin do enter the brain.28 Yet a large Mendelian randomization of about 1 million people found that genetic variants mimicking statins (HMGCR), ezetimibe (NPC1L1) and CETP inhibition were linked to 76%, 82% and 70% lower dementia risk per roughly 40 mg/dL lower non-HDL cholesterol, while PCSK9-type variants showed no benefit. These are lifelong genetic effects, not drug trials.29
  • Plaque is another yardstick. The group has a summary graphic of medication strategies shown to regress plaque in randomized trials, tagged with statins, PCSK9 inhibitors, ezetimibe, EPA and colchicine; the olezarsen result shows that a big change in one lipid does not guarantee plaque change.730
Blood numbers moved, events did notMajor cardiovascular events on the drug versus placebo in three trials of drugs that hit their blood targets
DrugPlacebo
Pelacarsen, Lp(a)HORIZON (Lp(a) lowered)12.3%12.1%
Ziltivekimab, ZEUS (CRP and IL-6 lowered)17.6%17.7%
Dalcetrapib (HDL raised)8.3%8.0%
Lp(a)HORIZON ran 4.7 years. Torcetrapib, another CETP inhibitor, raised deaths from 59 to 93 in 15,067 patients. Source: 4
Show data
DrugPlacebo
Pelacarsen, Lp(a)HORIZON (Lp(a) lowered)12.3%12.1%
Ziltivekimab, ZEUS (CRP and IL-6 lowered)17.6%17.7%
Dalcetrapib (HDL raised)8.3%8.0%
The JACC review's central illustration that the group shared: imaging methods used to measure plaque, and the drug strategies linked to plaque regression (statins, ezetimibe, PCSK9 and CETP inhibitors, EPA and colchicine), plus exercise.
The JACC review's central illustration that the group shared: imaging methods used to measure plaque, and the drug strategies linked to plaque regression (statins, ezetimibe, PCSK9 and CETP inhibitors, EPA and colchicine), plus exercise.30

What this means for you

  • If LDL remains above target on a statin, the guideline path described in the group is to add ezetimibe first, then consider bempedoic acid, a PCSK9 antibody or inclisiran. Discuss which step suits your risk with your doctor.1012
  • If you cannot tolerate statins, the group's list of alternatives is ezetimibe, bempedoic acid, inclisiran, Repatha and Praluent; bempedoic acid has outcome data in statin-intolerant people, while PCSK9 antibodies have outcome proof mainly on top of statins.11113
  • If you take bempedoic acid, the reported side effects to ask about are gout, gallstones and changes in uric acid, creatinine and liver enzymes.1
  • Treat obicetrapib as new and not yet outcome-proven: it is approved in the EU for LDL lowering, but heart-attack results and any Alzheimer's benefit are still to be shown.23
  • Lp(a) is genetic; the group's explainer suggests asking your doctor for a single test, because the number does not change much but guides how aggressively to manage other risks. Lp(a)-lowering drugs have not yet shown fewer events.49
  • Do not judge a drug by HDL or triglycerides alone; the group's admins focus on LDL and ApoB, and on insulin sensitivity for triglycerides and HDL.2026

Frequently asked questions

Is obicetrapib available now?

It was approved by the European Commission on 21 September 2026, reported as the first approval anywhere, in two forms (obicetrapib alone and combined with ezetimibe). The posts do not describe approval elsewhere.2

Does raising HDL protect the heart?

Not according to the trials the group cites: five major HDL-raising trials failed to cut events, and torcetrapib increased deaths.46 Obicetrapib is mainly valued for its LDL-C lowering, not for raising HDL.2

Can PCSK9 drugs replace statins?

Louis says no outcome trial supports that. Their proven benefit is on top of statins, and guidelines recommend them alone mainly for people who cannot take statins.11

Why did the Lp(a) drug not reduce heart attacks?

The posts say it is not yet clear. Possible explanations include very well-controlled LDL in participants, short treatment duration, late treatment and the need for subgroup analysis.427

Do cholesterol drugs also lower inflammation?

Yes, to differing degrees: hsCRP fell on average by about 20% with bempedoic acid, 17.3% with statins and 3.2% with ezetimibe, according to a meta-analysis Louis cited.1516

The evidence behind this summary30 studies · 2 meta-analyses · 17 trials · 2 MR · 2 observational

The 30 group posts cited above discuss 30 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 2Randomized trials 17Mendelian randomization 2Observational studies 2Reviews & guidelines 5Animal & lab studies 1Other sources 1

Strongest evidence discussed

All 30 studies and sources
Sources from the group (30)
  1. Bempedoic acid cut CV events and may also dampen age-related inflammation Louis Nervegna · Jul 21, 2026 · Facebook
  2. Obicetrapib gets first approval worldwide in the EU, lowering LDL up to 40-50% Louis Nervegna · Sep 21, 2026 · Facebook
  3. Obicetrapib lowers LDL and raises HDL on top of statins, but outcome benefit is unproven Louis Nervegna · May 23, 2026 · Facebook
  4. Pelacarsen (Lp(a)HORIZON) and ziltivekimab (ZEUS) cut their targets but not heart events Louis Nervegna · Nov 13, 2026 · Facebook
  5. Lowering LDL does not guarantee fewer events: niacin and CETP inhibitors failed on MACE Louis Nervegna · Aug 14, 2026 · Facebook
  6. Drugs that raise HDL have repeatedly failed to cut cardiovascular events Louis Nervegna · Jun 12, 2026 · Facebook
  7. Olezarsen cut triglycerides 64% but did not change plaque in ESSENCE-TIMI 73b imaging Louis Nervegna · Mar 31, 2026 · Facebook
  8. Lepodisiran siRNA cut Lp(a) by 93.9% at 400 mg in a 320-person NEJM trial Louis Nervegna · May 07, 2025 · Facebook
  9. Lp(a) explained: an LDL particle with a tail, genetic, unaffected by standard drugs Louis Nervegna · Sep 03, 2026 · Facebook
  10. 2025 ESC/EAS update: where ezetimibe, bempedoic acid, PCSK9 drugs and inclisiran fit Louis Nervegna · Oct 19, 2025 · Facebook
  11. No trial has shown PCSK9 inhibitors lower heart attack risk without statins Louis Nervegna · Aug 13, 2026 · Facebook
  12. 2025 ACC/AHA ACS guideline: high-intensity statin plus a non-statin if LDL is 70 or above Louis Nervegna · Feb 27, 2025 · Facebook
  13. Statin-intolerant? Options include ezetimibe, bempedoic acid, inclisiran, PCSK9 antibodies Louis Nervegna · May 30, 2026 · Facebook
  14. Ezetimibe beyond statins: fewer events, no mortality gain in trials, registry benefits Gokhan Can · Nov 07, 2024 · Facebook
  15. Statins, bempedoic acid, ezetimibe, fibrates and PCSK9 inhibitors all lower hsCRP Louis Nervegna · Dec 28, 2025 · Facebook
  16. Meta-analysis: statins, bempedoic acid, ezetimibe and omega-3 lower CRP independent of LDL Gokhan Can · Feb 19, 2024 · Facebook
  17. PCSK9 inhibition may slow cardiometabolic aging beyond lowering cholesterol Louis Nervegna · Dec 21, 2023 · Facebook
  18. CETP inhibitor obicetrapib slowed p-tau217 accumulation in the BROADWAY analysis Louis Nervegna · Sep 05, 2025 · Facebook
  19. HDL and ApoA-I raising therapies repeatedly failed, so HDL is probably not directly causal Louis Nervegna · Mar 11, 2024 · Facebook
  20. Why insulin resistance lowers HDL, and why improving insulin sensitivity beats chasing HDL Louis Nervegna · Mar 21, 2024 · Facebook
  21. Obicetrapib may prevent both heart disease and Alzheimer's Louis Nervegna · Jul 07, 2026 · Facebook
  22. Obicetrapib lowered Alzheimer's marker p-tau217, most in APOE4 carriers (BROADWAY) Louis Nervegna · Jul 24, 2026 · Facebook
  23. Obicetrapib improved Alzheimer's biomarkers, most in APOE4/4 carriers (BROADWAY substudy) Louis Nervegna · May 23, 2026 · Facebook
  24. CETP inhibitors might help prevent Alzheimer's and Lewy body dementia in APOE4 carriers Louis Nervegna · May 24, 2026 · Facebook
  25. Olezarsen cut triglycerides 64% and remnant cholesterol 72%, but plaque did not change Gokhan Can · Mar 30, 2026 · Facebook
  26. Lowering triglycerides alone does not shrink plaque: olezarsen cut TG 64%, plaque flat Louis Nervegna · May 20, 2026 · Facebook
  27. Why lowering Lp(a) failed to cut heart attacks in the HORIZON trial, per Nature Louis Nervegna · Nov 03, 2026 · Facebook
  28. Only lipophilic statins like atorvastatin enter the brain; PCSK9 drugs and ezetimibe don't Louis Nervegna · Oct 18, 2025 · Facebook
  29. Statin- and ezetimibe-like gene variants linked to 76-82% lower dementia risk per 40 mg/dL Louis Nervegna · Aug 28, 2026 · Facebook
  30. Medication strategies that have regressed arterial plaque in high-quality RCTs Louis Nervegna · Aug 12, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary